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Purpose: Clinical trials in radiation therapy-induced nausea and 
vomiting (RINV) appear to have varied methodologies, endpoints 
and outcome measures. This variability hinders implementation 
of trial results. A comprehensive analysis of RINV trial design 
elements is lacking. 
Methods and Materials: Ovid versions of the Cochrane Central 
Register of Controlled Trials, the Cochrane Database of 
Systematic Reviews, EMBASE and MEDLINE to first quarter 2011 
were searched for randomized trials of RINV management 
strategies. 
Results: From 599 references in the initial database search we 
selected 34 trials for analysis that collectively randomized 4529 
patients. Twenty-eight trials (82%) were published prior to the 
year 2000. Twenty-seven trials (79%) involved multiple fraction 
radiation therapy (RT) and seven (21%) single fraction RT. 
Twenty-four trials (71%) evaluated prophylactic interventions 
and nine (26%) rescue interventions. Thirty-three trials (97%) 
evaluated pharmacologic interventions. Nausea was not defined 
in any trial but was reported as a stand-alone symptom in 26 
trials (76%) and was graded in 20 (59%), with discrete choice 
categorical qualitative scales being the most common method. 
Vomiting was defined in three trials (9%), reported as a stand-
alone symptom in 17 (47%) and was graded in seven (21%), with 
continuous numerical scales being the most common method. 
Retching was defined in three trials (9%), was not reported as a 
stand-alone symptom in any trial and was graded in one (3%). 
Twenty-one trials (62%) created compound symptom measures 
that combined individual symptoms. Fifteen trials (44%) reported 
on “emetic episodes/events” but only nine of these defined 
them. Seventeen trials (50%) reported on complicated endpoints 
such as “response,” “control” and “success” that factored in 
multiple symptom or compound symptom measures, but seven of 
these did not define them comprehensively. Only 10 trials (29%) 
defined a primary endpoint a priori. 
Conclusions: Methodologies, endpoints and outcome measures 
varied considerably among 34 randomized trials in RINV. 
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Purpose: To systematically review the efficacy and safety of 
various antiemetics in prophylaxis of radiation-induced nausea 
and vomiting (RINV). 
Methods and Materials: A literature search of Ovid MEDLINE, 
EMBASE and Cochrane CENTRAL was performed to identify 
randomized controlled trials (RCTs) that evaluated the efficacy 
of prophylaxis for RINV in patients receiving radiotherapy to 
abdomen/pelvis, including total body irradiation (TBI). Primary 
endpoints were complete control of nausea and complete control 
of vomiting during acute and delayed phases. Secondary 
endpoints included use of rescue medication, quality of life and 
incidence of adverse events. 
Results: Seventeen RCTs were identified. Among patients 
receiving radiotherapy to abdomen/pelvis, our meta-analysis 
showed that 5-hydroxytryptamine-3 receptor antagonists (5HT3 
RAs) were significantly more efficacious than placebo and 
dopamine antagonists in both complete control of vomiting (OR 
0.49, 95% confidence interval [CI] 0.33-0.72 and OR 0.17, 95% CI 
0.05-0.58 respectively) and complete control of nausea (OR 0.43, 
95% CI 0.26-0.70 and OR 0.46, 95% CI 0.24-0.88 respectively). 
5HT3 RAs were also more efficacious than rescue therapy and 
dopamine antagonists plus dexamethasone. The addition of 
dexamethasone to 5HT3 RA compared to 5HT3 RA alone provides 
a modest improvement in prophylaxis of RINV. Among patients 
receiving TBI, 5HT3 RA was more effective than other agents 
(placebo, combination of metoclopramide, dexamethasone and 
lorazepam). 
Conclusions: 5HT3 RAs are more effective than other 
antiemetics for prophylaxis of RINV in patients receiving 
radiotherapy to abdomen/pelvis and TBI. Future RCTs should 
investigate the efficacy of newer agents such as aprepitant in 
addition to 5HT3 RAs in prophylaxis of RINV during both acute 
and delayed phases. 
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Purpose: The British Columbia Cancer Agency radiotherapy (RT) 
program started the Prospective Outcomes and Support Initiative 
(POSI) at all six centres in 2013 to collect and utilize patient 
reported outcomes (PROs) for immediate clinical care, quality 
improvement, and research. We sought to explore the feasibility 
and utility of using PRO two years after the start of POSI. 
Methods and Materials: PROs were collected at time of CT 
simulation via tablet or radiation therapist questions, and 2-4 
weeks post-RT over the phone with a registered nurse (RN). 
Descriptive Statistics were used to present accrual and utility of 
PRO data. Comparison in accrual rates between categories was 
performed with chi square tests. Mean differences in time that 
RNs spent on POSI phone calls were compared with t-tests. 
Multivariable logistic regression modeling identified factors 
associated with successful accrual. 
Results: From May 2013 to July 2015, 2849 patients were 
approached by POSI on 5,847 occasions for patients treated with 
RT for bone metastases (81%), brain metastases (12%), and 
incurable lung cancer (7%). The accrual rate for all encounters 
was 76% (n = 4904), ranging from 73% to 87% depending on cancer 
centre (p < 0.001), and highest amount patients with bone 
metastases (78%), followed by lung cancer (75%) and brain 
metastases (65%; p < 0.001). Patients were significantly less 
likely to be successfully accrued at follow up compared to 
baseline (OR = 0.21; 95% CI = 0.18 – 0.24; p < 0.001), as were 
those with brain metastases (OR = 0.50; 0.41 – 0.1; p < 0.001). 
During the study period RNs made 2042 telephone follow up calls, 
totaling 250 RN hours, to both collect PRO, and subsequently use 
these PRO to guide follow up care. The RN-reported mean time 
to complete the follow up call was highest with brain metastases 
(13.1 minutes) compared to lung cancer (8.2 minutes) and bone 
metastases (6.7 minutes), which was highly significant (p < 
0.001). The RN phone calls that required the RN to offer 
additional support were significantly longer than phone calls 
where no support was needed (mean 12.1 versus 6.4 minutes; p 
< 0.001). From this database we have demonstrated similar 
patient reported pain improvement with single versus multiple 
fraction RT (presented previously), and have used data to lead 
quality improvement initiatives, such as identifying patients who 
did not have a dexamethasone weaning protocol. Other quality 
improvement and research utility of the POSI database will be 
described. 
Conclusions: Population-based collection and utilization of PRO 
for clinical care, quality improvement, and research is feasible 
and associated with only a modest increase in resources and 
workload. Further research is needed on how to best incorporate 
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PRO data into care processes and assess how the use of PRO in 
clinical care impacts on patient outcomes. 
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Purpose: To describe the case mix, intervention efficacy and 
prognosis of patients with advanced lung cancer attending a Fast 
Track Lung (FTL) clinic that was established to improve 
timeliness of access to palliative RT. 
Methods and Materials: Pre-treatment and treatment 
information was prospectively collected on FTL patients seen 
from January 2014 to December 2015. Palliative RT use was 
decided based on clinical/radiologic information suggesting that 
one or more specific symptoms were reasonably likely to be 
helped. Phone follow up by a nurse 1- 2 months later assessed 
the effect of RT on each index symptom. 
Results: Two hundred and fourteen patients were assessed a 
total of 310 times, a mean of 1.5 times per patient (range 1- 8). 
Eighty-six percent had non-small cell histologies (71% 
adenocarcinoma, 22% squamous cell carcinoma). Most were 
ECOG 2 (30%) or 3 (46%) at the time of first presentation. Median 
survival from initial FTL consult was 3.2 months (95% CI 2.2 – 3.6) 
for the entire group; for ECOG 0 – 1, it was 12.3 months (95% CI 
7.4 – 16.2) and for ECOG 3 – 4, 1.8 months (95% CI 1.5 – 2.2). 
EGFR mutation positive patients had a median survival of 12.5 
months (95% CI 4.3 – 39.8). 224 of the 310 clinic visits resulted in 
palliative RT to at least one site, of which 161 (72%) had phone 
follow up. Three hundred and ninety courses of RT were 
delivered, a mean of 1.8 per patient, (range 0 – 13). Forty-nine 
percent of RT courses were delivered to bony sites other than 
ribs, 22% to the chest, 14% to the chest wall/ribs and 10% to the 
brain. Thirty-once percent were single fractions and 92% were < 
5 fractions. Median dose was 20 Gy and the median number of 
fractions was 5. Among patients receiving RT to one or more 
concurrent site(s), 80% reported some benefit. Seventy-seven 
percent of patients receiving RT to the chest reported 
improvement in at least one index symptom. This varied by 
symptom (e.g. dysphagia 33%, cough 82%, hemoptysis 100%). 
Eighty percent of treated bone mets became less painful. If one 
assumes that every patient without follow up information had no 
benefit, still 59% were helped. 
Conclusions: Palliative RT, generally with 5 or fewer fractions, 
helped most patients with clinically or radiologically targetable 
symptoms who attended a dedicated Fast Track Lung clinic. 
Phone follow up is a feasible way to obtain patient or family 
reported outcome information. Median survival was short, 
although considerably longer in patients with good performance 
status and/or an EGFR mutation, in whom the potential benefits 
of more intensified palliative RT should be investigated.  
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Purpose: An interdisciplinary clinic was established at our 
regional cancer centre in 2011 for patients diagnosed with brain 
metastases. A clinic nurse/clinical nurse specialist, a spiritual 
care/patient-family counselor, a palliative care physician or 
nurse practitioner, and a radiation oncologist provided team-
based consultations. Other clinical or support services were 
engaged as needed. A self-administered feedback survey was 
given to the patient/family after consultation for quality 
improvement and program evaluation. We summarized the 
feedback, with an examination of themes that emerged through 
the comments given. 
Methods and Materials: Between July 2012 and December 2015, 
384 patients with/without family caregivers were seen at our 
outpatient palliative brain metastases clinic for consultation and 
management. A post-consultation feedback questionnaire, 
developed by team consensus, was framed to solicit satisfaction 
with: a) understanding of illness and options; b) symptom 
control; c) decision making; and d) care coordination. Items were 
rated on a 5-point Likert scale, anchored between “Strongly 
Agree” and “Strongly Disagree”. A free text comment section 
was also included. Questionnaires were given at the end of 
consultation with a self-addressed and stamped envelope for 
anonymous return. Numeric results are summarized in a 
frequency table and written comments are encoded by key words 
that indicate values and preferences. 
Results: Eighty-four questionnaires were received (22% response 
rate), 51/84 (61%) with written comments (median word count 
26, maximum 139). Satisfaction (“agree” or “strongly agree”) 
was indicated in 85% or more of questionnaires for 11 of 13 items. 
In contrast, dissatisfaction (“disagree” or “strongly disagree”) 
was indicated in less than 10% of questionnaires returned. The 
item of most dissatisfaction (9% of questionnaires) was about 
receiving “as much information about my prognosis as I wanted.” 
The most common key words of value were team approach, 
informative, respect, and professionalism. Comments expressing 
frustrations included poor communication, lack of clarity of 
treatment impact on prognosis, waiting time for care facility, 
tiring consultation process, missing prescription, and discrepancy 
between anticipated and actual cause of death.  
Conclusions: Interdisciplinary, team-based consultation and 
care was rated highly among questionnaire respondents 
confronting the diagnosis of brain metastases, a serious and life-
limiting illness. A small proportion of patients and families 
experienced gaps in communication and expectations. Team-
approach, information and respect appeared to be the most 
valued features of our consultative process. 
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Purpose: A provincial initiative to streamline and standardize 
radiation therapy (RT) processes was initiated in Q1 2015 with 
the ultimate goal of measuring treatment and operational 
outcomes. Two tertiary centres using Varian’s Record and Verify 
systems since the 1980’s have been slow to incorporate some of 
the paper-light functions and features available. Two community 
centres (opening in 2010 and 2014) introduced more of a paper-
light environment. The operational and environmental 
differences between facilities have resulted in disparate 
processes, software, and definitions in RT practice across the 
province. 
Methods and Materials: The first challenge was to establish a 
provincial Steering Committee (SC) with front-line 
representatives from each of three disciplines and all four RT 
facilities. The SC is comprised of: three co-chairs (medical 
physicist, radiation oncologist and radiation therapist), five 
0.2/0.4 FTE project coordinators (PC) (radiation therapists), 0.5 
FTE project manager (PM), two 0.5 FTE process improvement 
specialists (PIs) (one for the North and one for the South), a 
Varian Clinical Consultant, Executive sponsors, and additional 
representatives from each discipline at each RT centre. A core 
group (CG) of the SC consists of three co-chairs, PM, PCs, PIs, 
and Varian. Local working groups were established at each RT 
center with three co-chairs, who also sit on the SC to ensure 
